News and Announcements
Browse the articles below to learn more about our faculty’s latest achievements, awards and honors.
09.01.2026In the following interview, conducted at the2026 American Urological Association (AUA) Annual Meeting , Joshua Halpern, MD, MS, discusses the evidence supporting the clinical reliability of mail-in semen analysis and highlighted the patient populations most likely to benefit from at-home testing. Halpern is the regional medical director in the Northeast and chief scientific officer for Posterity Health. He is also an adjunct assistant professor of urology at Northwestern Medicine.
08.26.2026Ashley Ross, MD, PhD, of Northwestern Medicine, discusses the emerging role of next-generation sequencing (NGS) in high-risk localized prostate cancer and biochemical recurrence. Early genomic testing may provide valuable prognostic insight, support clinical trial enrollment, and inform more personalized treatment strategies across the disease course.
08.04.2026Northwestern Memorial Hospital has once again been named to the U.S. News & World Report Best Hospitals Honor Roll, marking its 15th consecutive year of recognition. The distinction reflects sustained excellence across a broad range of specialties and reinforces Northwestern Medicine’s commitment to delivering high-quality, patient-centered care.
07.30.2026Adam Murphy, MD, of Northwestern Medicine, discusses the evolving role of artificial intelligence in urology, noting that while AI tools are increasingly integrated into clinical workflows, their real-world impact remains modest. Early data suggest gains in efficiency, particularly with documentation, but highlight the need for continued evaluation as adoption expands.
07.28.2026A Northwestern Medicine study examined the impact of prebiopsy MRI and site-level variation on surgical treatment for prostate cancer. Findings suggest that MRI use prior to biopsy is associated with higher tumor stage and grade at surgery, while also reducing rates of disease upgrading—indicating improved diagnostic accuracy and patient selection.
07.17.2026A recent study found that patients undergoing HoLEP after prior UroLift experience greater preoperative urinary symptoms, but achieve similar postoperative outcomes compared to those undergoing HoLEP as a first-line treatment.
07.16.2026Jamie Michael, MD, a Northwestern Medicine urology resident, highlights research on the use of multiparametric MRI and genomic testing in active surveillance for prostate cancer. Findings suggest that combining these approaches may improve risk stratification and support more personalized management of patients on surveillance.
07.14.2026Investigators at Northwestern Medicine evaluated outcomes of holmium laser enucleation of the prostate (HoLEP) in patients with prior prostatic urethral lift (PUL). The study demonstrates that HoLEP is a safe and effective treatment option following PUL, with perioperative outcomes comparable to those undergoing primary HoLEP. Patients with prior PUL exhibited a higher baseline urinary symptom burden and may require continued medical management, underscoring the importance of comprehensive patient counseling and individualized care planning.
07.10.2026Dr. Amy Krambeck discusses that CVAC and FANS reflect different surgical philosophies—dusting vs fragmentation—with distinct ergonomic trade-offs and shared intrarenal pressure risks that urologists must actively monitor.
06.30.2026A large international clinical trial has found that adding the drug apalutamide to standard hormone therapy before and after prostate cancer surgery significantly improves outcomes for men with high-risk disease, according to details published in The New England Journal of Medicine.
06.16.2026Jenny N. Guo, MD, highlights findings from a retrospective propensity-matched study evaluating hemi-holmium laser enucleation of the prostate (hemi-HoLEP) as an option for patients who had previously undergone pelvic radiation therapy.
06.10.2026A Northwestern Medicine study has offered new clues as to why immunotherapy works well for some bladder cancer patients but fails for others, according to a study published in the Journal of Clinical Investigation.
06.09.2026Joshua Meeks describes a phase 1/2 trial of an intravesical anti-nectin-4 antibody-drug conjugate with a topoisomerase inhibitor payload.- 05.15.2026
A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology.
05.15.2026Joshua J. Meeks, MD, PhD, and Edward M. Schaeffer, MD, PhD discussed findings from a real-world registry study evaluating the outcomes of BCG rechallenge in patients with non-muscle–invasive bladder cancer (NMIBC) who experienced disease recurrence within 12 months of initial BCG therapy.
05.15.2026A new study may pave the way toward more personalized treatments for patients with high‑risk bladder cancer, according to a study published in European Urology.
04.15.2026Northwestern Medicine scientists have uncovered an unexpected role for a well-known cancer-related protein, revealing a new layer of genetic regulation that could reshape how certain cancers are treated.
04.09.2026Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways in prostate cancer cells and drives tumor progression, underscoring its potential as a therapeutic target, according to a recent study published in Nature Communications.
02.09.2026Scientists in the laboratory of Rendong Yang, PhD, have developed a new large language model that can interpret transcriptomic data in cancer cell lines more accurately than conventional approaches, as detailed in a recent study published in Nature Communications.
12.17.2025Nicholas Deebel, MD, discusses current evidence-based approaches to diagnosing and managing post-vasectomy pain syndrome, emphasizing conservative treatment, shared decision-making, and the role of psychosocial support in care.
12.04.2025A Northwestern Medicine study published in the Journal of Clinical Investigation has uncovered a connection between a well-known cancer-related protein and a major RNA modification process, which may inform new treatment strategies against prostate cancer.
09.30.2025Biological markers may help predict which patients will benefit most from specific therapies to treat prostate cancer, according to a study published in the journal Cell.